RIGL Quote, Financials, Valuation and Earnings

Checkpoint Therapeutics has a net margin of 24.9% compared to Rigel Pharmaceuticals's net margin of -16268.29%. Rigel Pharmaceuticals's return on equity of -- beat Checkpoint Therapeutics's return on equity of --.

Rigel Pharmaceuticals has a consensus price target of $33.67, signalling upside risk potential of 104.16%. On the other hand Checkpoint Therapeutics has an analysts' consensus of $4.33 which suggests that it could grow by 7.26%. Given that Rigel Pharmaceuticals has higher upside potential than Checkpoint Therapeutics, analysts believe Rigel Pharmaceuticals is more attractive than Checkpoint Therapeutics.

Rigel Pharmaceuticals has a beta of 1.319, which suggesting that the stock is 31.928% more volatile than S&P 500. In comparison Checkpoint Therapeutics has a beta of 1.211, suggesting its more volatile than the S&P 500 by 21.135%.

Rigel Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Checkpoint Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Rigel Pharmaceuticals pays -- of its earnings as a dividend. Checkpoint Therapeutics pays out -- of its earnings as a dividend.

Rigel Pharmaceuticals quarterly revenues are $57.6M, which are larger than Checkpoint Therapeutics quarterly revenues of $41K. Rigel Pharmaceuticals's net income of $14.3M is higher than Checkpoint Therapeutics's net income of -$9.7M. Notably, Rigel Pharmaceuticals's price-to-earnings ratio is 17.54x while Checkpoint Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Rigel Pharmaceuticals is 1.63x versus -- for Checkpoint Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals has a net margin of 24.9% compared to Rigel Pharmaceuticals's net margin of -49.65%. Rigel Pharmaceuticals's return on equity of -- beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Rigel Pharmaceuticals has a consensus price target of $33.67, signalling upside risk potential of 104.16%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 44.56%. Given that Rigel Pharmaceuticals has higher upside potential than NovaBay Pharmaceuticals, analysts believe Rigel Pharmaceuticals is more attractive than NovaBay Pharmaceuticals.

Rigel Pharmaceuticals has a beta of 1.319, which suggesting that the stock is 31.928% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.897, suggesting its less volatile than the S&P 500 by 10.271%.

Rigel Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Rigel Pharmaceuticals pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Rigel Pharmaceuticals quarterly revenues are $57.6M, which are larger than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Rigel Pharmaceuticals's net income of $14.3M is higher than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Rigel Pharmaceuticals's price-to-earnings ratio is 17.54x while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Rigel Pharmaceuticals is 1.63x versus 0.16x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of 24.9% compared to Rigel Pharmaceuticals's net margin of --. Rigel Pharmaceuticals's return on equity of -- beat Palatin Technologies's return on equity of --.

Rigel Pharmaceuticals has a consensus price target of $33.67, signalling upside risk potential of 104.16%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 1557.59%. Given that Palatin Technologies has higher upside potential than Rigel Pharmaceuticals, analysts believe Palatin Technologies is more attractive than Rigel Pharmaceuticals.

Rigel Pharmaceuticals has a beta of 1.319, which suggesting that the stock is 31.928% more volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.896, suggesting its less volatile than the S&P 500 by 10.45%.

Rigel Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Rigel Pharmaceuticals pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

Rigel Pharmaceuticals quarterly revenues are $57.6M, which are larger than Palatin Technologies quarterly revenues of --. Rigel Pharmaceuticals's net income of $14.3M is higher than Palatin Technologies's net income of --. Notably, Rigel Pharmaceuticals's price-to-earnings ratio is 17.54x while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Rigel Pharmaceuticals is 1.63x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Retractable Technologies has a net margin of 24.9% compared to Rigel Pharmaceuticals's net margin of -18.58%. Rigel Pharmaceuticals's return on equity of -- beat Retractable Technologies's return on equity of -16.83%.

Rigel Pharmaceuticals has a consensus price target of $33.67, signalling upside risk potential of 104.16%. On the other hand Retractable Technologies has an analysts' consensus of -- which suggests that it could fall by --. Given that Rigel Pharmaceuticals has higher upside potential than Retractable Technologies, analysts believe Rigel Pharmaceuticals is more attractive than Retractable Technologies.

Rigel Pharmaceuticals has a beta of 1.319, which suggesting that the stock is 31.928% more volatile than S&P 500. In comparison Retractable Technologies has a beta of 2.279, suggesting its more volatile than the S&P 500 by 127.852%.

Rigel Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Retractable Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Rigel Pharmaceuticals pays -- of its earnings as a dividend. Retractable Technologies pays out -1.94% of its earnings as a dividend.

Rigel Pharmaceuticals quarterly revenues are $57.6M, which are larger than Retractable Technologies quarterly revenues of $10.3M. Rigel Pharmaceuticals's net income of $14.3M is higher than Retractable Technologies's net income of -$1.9M. Notably, Rigel Pharmaceuticals's price-to-earnings ratio is 17.54x while Retractable Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Rigel Pharmaceuticals is 1.63x versus 0.63x for Retractable Technologies. Usually stocks with elevated PS ratios are considered overvalued.